文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

免疫功能低下患者急性低氧性呼吸衰竭:Efraim 多国前瞻性队列研究

Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study.
PubMed 文献 · Intensive Care Med · 2017-09-25
一句话结论在免疫功能低下合并急性低氧性呼吸衰竭患者中,HFNC 可能影响插管率但不影响死亡率;未能明确病因与插管率和死亡率升高相关。

该多国前瞻性观察性队列研究纳入16个国家68个中心的1611例免疫功能低下合并急性低氧性呼吸衰竭患者,评估初始氧疗策略对插管率和死亡率的影响。入住时915例(56.8%)未插管,分别接受标准氧疗、HFNC、NIV或NIV+HFNC。倾向性评分匹配后,HFNC对插管率有影响(HR=0.77,95%CI 0.59-1.00,p=0.05),NIV无此影响。初始氧合策略不影响死亡率,但插管与死亡率相关,且不同插管条件风险不同。未能明确病因与插管率和死亡率升高均相关。

要点

  • 入住时未插管的915例(56.8%)中,标准氧疗496例(53.9%)、HFNC 187例(20.3%)、NIV 153例(17.2%)、NIV+HFNC 79例(8.6%)。
  • 倾向性评分匹配后,HFNC对插管率有影响(HR=0.77,95%CI 0.59-1.00,p=0.05),NIV对插管率无影响。
  • 初始氧合策略不影响死亡率;插管与死亡率相关,标准氧疗失败OR=4.16(2.91-5.93)、HFNC失败OR=5.54(3.27-9.38)、NIV失败OR=3.65(2.05-6.53)、NIV+HFNC失败OR=2.31(1.09-4.91)、一线插管OR=2.55(1.94-3.29)。
  • 未能明确ARF病因与插管(OR=1.46,1.09-1.98)和住院死亡率(OR=1.43,1.04-1.97)升高相关。
  • 住院死亡率独立相关因素包括年龄(OR=1.18/岁,1.09-1.27)、直接入住ICU(OR=0.69,0.54-0.87)、首日SOFA除外呼吸评分(OR=1.12/分,1.08-1.16)、PaO2/FiO2<100(OR=1.60,1.03-2.48)。

适用人群与场景

  • 16个国家68个中心收治的免疫功能低下合并急性低氧性呼吸衰竭成人患者,包括血液系统恶性肿瘤(51.9%)、实体瘤(35.2%)、系统性疾病(17.3%)和实体器官移植(8.8%)。
  • 入住时未插管者915例(56.8%),接受初始氧合策略为标准氧疗、HFNC、NIV或NIV+HFNC。

研究设计与关键结果

  • 多国前瞻性观察性队列研究,纳入16个国家68个中心共1611例免疫功能低下合并急性低氧性呼吸衰竭患者。
  • 入住时未插管915例(56.8%),初始氧合策略:标准氧疗496例(53.9%)、HFNC 187例(20.3%)、NIV 153例(17.2%)、NIV+HFNC 79例(8.6%)。
  • 与插管相关的因素:年龄(HR=0.92/岁,95%CI 0.86-0.99)、首日SOFA(HR=1.09/分,1.06-1.13)、首日PaO2/FiO2(HR=1.47,1.05-2.07)、ARF病因(肺孢子菌肺炎HR=2.11,1.42-3.14;侵袭性肺曲霉病HR=1.85,1.21-2.85;病因未明HR=1.46,1.09-1.98)。
  • 倾向性评分匹配后,HFNC对插管率有影响(HR=0.77,95%CI 0.59-1.00,p=0.05),NIV对插管率无影响。
  • ICU死亡率32.4%、住院死亡率44.1%、第90天死亡率56.4%。
  • 住院死亡率独立相关因素:年龄(OR=1.18/岁,1.09-1.27)、直接入住ICU(OR=0.69,0.54-0.87)、首日SOFA除外呼吸评分(OR=1.12/分,1.08-1.16)、PaO2/FiO2<100(OR=1.60,1.03-2.48)、ARF病因未明(OR=1.43,1.04-1.97)。
  • 初始氧合策略不影响死亡率;插管与死亡率相关,OR依插管条件不同:NIV+HFNC失败OR=2.31(1.09-4.91)、一线插管OR=2.55(1.94-3.29)、NIV失败OR=3.65(2.05-6.53)、标准氧疗失败OR=4.16(2.91-5.93)、HFNC失败OR=5.54(3.27-9.38)。

证据类型、等级与局限

  • 证据类型:多国前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,除选择适当的氧合装置外,临床医生应努力明确急性低氧性呼吸衰竭的病因。
  • 倾向性评分匹配后HFNC对插管率有影响(HR=0.77,95%CI 0.59-1.00,p=0.05),NIV对插管率无影响;初始氧合策略不影响死亡率。
  • 插管与死亡率相关,且不同插管条件OR不同:HFNC失败OR=5.54(3.27-9.38)、标准氧疗失败OR=4.16(2.91-5.93)、NIV失败OR=3.65(2.05-6.53)、一线插管OR=2.55(1.94-3.29)、NIV+HFNC失败OR=2.31(1.09-4.91)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In immunocompromised patients with acute hypoxemic respiratory failure (ARF), initial management aims primarily to avoid invasive mechanical ventilation (IMV).

METHODS: To assess the impact of initial management on IMV and mortality rates, we performed a multinational observational prospective cohort study in 16 countries (68 centers).

RESULTS: A total of 1611 patients were enrolled (hematological malignancies 51.9%, solid tumors 35.2%, systemic diseases 17.3%, and solid organ transplantation 8.8%). The main ARF etiologies were bacterial (29.5%), viral (15.4%), and fungal infections (14.7%), or undetermined (13.2%). On admission, 915 (56.8%) patients were not intubated. They received standard oxygen (N = 496, 53.9%), high-flow oxygen (HFNC, N = 187, 20.3%), noninvasive ventilation (NIV, N = 153, 17.2%), and NIV + HFNC (N = 79, 8.6%). Factors associated with IMV included age (hazard ratio = 0.92/year, 95% CI 0.86-0.99), day-1 SOFA (1.09/point, 1.06-1.13), day-1 PaO2/FiO2 (1.47, 1.05-2.07), ARF etiology (Pneumocystis jirovecii pneumonia (2.11, 1.42-3.14), invasive pulmonary aspergillosis (1.85, 1.21-2.85), and undetermined cause (1.46, 1.09-1.98). After propensity score matching, HFNC, but not NIV, had an effect on IMV rate (HR = 0.77, 95% CI 0.59-1.00, p = 0.05). ICU, hospital, and day-90 mortality rates were 32.4, 44.1, and 56.4%, respectively. Factors independently associated with hospital mortality included age (odds ratio = 1.18/year, 1.09-1.27), direct admission to the ICU (0.69, 0.54-0.87), day-1 SOFA excluding respiratory score (1.12/point, 1.08-1.16), PaO2/FiO2 < 100 (1.60, 1.03-2.48), and undetermined ARF etiology (1.43, 1.04-1.97). Initial oxygenation strategy did not affect mortality; however, IMV was associated with mortality, the odds ratio depending on IMV conditions: NIV + HFNC failure (2.31, 1.09-4.91), first-line IMV (2.55, 1.94-3.29), NIV failure (3.65, 2.05-6.53), standard oxygen failure (4.16, 2.91-5.93), and HFNC failure (5.54, 3.27-9.38).

CONCLUSION: HFNC has an effect on intubation but not on mortality rates. Failure to identify ARF etiology is associated with higher rates of both intubation and mortality. This suggests that in addition to selecting the appropriate oxygenation device, clinicians should strive to identify the etiology of ARF.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Azoulay E, Pickkers P, Soares M, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med. 2017. PMID: 28948369. doi:10.1007/s00134-017-4947-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。